Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
In a recent update, Eli Lilly and Company announced a Phase 1 clinical study aimed at evaluating the bioavailability of three different formulations of LY4100511 (DC-853). The study, officially titled ‘A Phase 1, Open-label, Randomized, Four-way Crossover Study to Assess the Relative Bioavailability of Two Phase 3 LY4100511 (DC-853) Tablet Formulations Compared With the Phase 2 LY4100511(DC-853) Tablet Formulation, With and Without a Proton Pump Inhibitor in Healthy Participants,’ seeks to determine how these formulations are absorbed in the body, both alone and when combined with a proton pump inhibitor.
The study tests the oral administration of LY4100511, a drug under investigation, both alone and in combination with Rabeprazole, a proton pump inhibitor. This combination aims to assess whether the presence of Rabeprazole affects the drug’s bioavailability.
Conducted as an interventional study, it employs a randomized, crossover design without masking, focusing on basic science. This approach allows each participant to receive multiple formulations, providing comparative data on bioavailability.
The study began on April 8, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 23, 2025, indicating ongoing recruitment.
This study could influence Eli Lilly’s stock performance, as successful results may enhance the company’s pipeline and competitive positioning in the pharmaceutical market. Investors should monitor updates, as positive outcomes could boost market confidence.
The study is currently recruiting, with further details available on the ClinicalTrials portal.